AlzeCure Pharma AB: Positive results from the Phase Ib clinical study of NeuroRestore ACD856, under development for Alzheimer's

Source Summary

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced that...